New patent application

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

New patent application

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, announces that a second patent application has been filed in the field of systems and methods for assessing cognitive function describing ways of using wearable technology, smartphones and other consumer electronics to measure cognitive function in peoples' own homes.

By mapping data from proprietary cognitive assessments to usage and behavioural trends of new devices and popular games the invention will monitor cognitive health and detect impairments such as ADHD, depression and dementia before noticeable symptoms develop. This would have application for both consumer-led mental health management and in improving pharmaceutical drug development through long-term monitoring of cognitive function.

This patent will extend the Company's IP asset estate adding to the technology value of the Company. The method of using new consumer technologies to monitor brain function and provide an early indication of impairment is highly innovative and is an area of significant growth potential for future products and commercial partnerships.

Using novel devices to monitor cognitive function and identify early deterioration is in line with the Company's strategic vision to become a leader in cognitive assessment technology in global healthcare markets. This follows another of the Company's recently filed patents surrounding the use of wearable technology for assessing cognitive function and symptoms of neurological and neuropsychiatric conditions, announced on May 6 2015.

Cambridge Cognition has a proven record of innovation, having recently introduced the first clinically approved touchscreen assessment for Alzheimer's disease into the NHS, which has now been used to test over 20,000 patients and developed a portfolio of cloud-based cognitive assessment products to enhance safe and effective pharmaceutical development. The global wearable healthcare market is expected to expand to $41 billion by 2020, from $2 billion in 2014 (Soreon Research, 2014) corroborating the Company's recent investment in IP assets and strategic development programmes.

Steven Powell, Chief Operating Officer of Cambridge Cognition, said: "The unique technology around this patent allows the detection of cognitive impairments to be performed on a continuous basis, without time, expense or inconvenience for the subject or healthcare provider. Ubiquitous monitoring of big data using our cloud technology can enable interventions to be immediate and will have a significant positive impact on patient care, empowering more effective management of mental health and wellbeing."

Enquiries:

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic scientists in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing. Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families.